Metformin use in diabetic patients with chronic renal failure. It is time for change

Authors

  • Fernando Antonio de Almeida PUC-SP

Keywords:

Diabetes mellitus, chronic renal insufficiency, metformin, hypoglycemic agents

Abstract

Introduction: cardiovascular complications are the leading causes of death in patients with chronic kidney disease from stages 2 or 3 to stage 5 (end stage renal disease), accounting for about 50% of deaths in this group of patients. The disease in stage 5 is characterized by glomerular filtration rate lower than 15 mL/min/1.73m² and its main causes are hypertension and Diabetes mellitus type 2. Objective: to describe the changes in the electrocardiogram of patients with chronic kidney disease stage 5 at the moment they start dialysis and correlate them with the underlying disease that caused chronic kidney disease. Results: the electrocardiograms of 199 patients from a single dialysis center in a 4-year period were evaluated. Most patients have chronic kidney disease caused by Diabetes mellitus type 2 (36.5%), hypertension (30%) and glomerulopathies (12%). We observed only 12% of electrocardiograph exams with normal tracing. The most common changes were the left atrial enlargement (31%), left ventricular hypertrophy (30%), altered ventricular depolarization by hyperkalemia (26%) and QTc prolonged interval. Left ventricular hypertrophy was more prevalent in patients with hypertension as a cause of chronic kidney disease and the strain fairly common pattern (47% of cases with left ventricular hypertrophy). Conclusion: the electrocardiograph changes are very prevalent in patients with stage 5 chronic kidney disease and must be known by the professionals who take care of them.

Downloads

Download data is not yet available.

Author Biography

Fernando Antonio de Almeida, PUC-SP

Professor do Depto. de Medicina FCMS/PUC-SP

References

U. S. Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Application number: 20 - 357/S019: final printed label ing: Glucophage (metformin hydrochloride) [Internet]. Silver Spring: FDA; 2015 [acesso em 19 fev. 2015]. Disponível em: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20357S019_Glucophage_prntlbl.pdf.

Clodridrato de Metformina: 500/850 mg [bula de remédio na Internet]. Xavier MAL, farmacêutico responsável. Montes Claros (MG): Biobrás; 2015 [acesso em 19 fev. 2105]. Disponível em: http://www.novonordisk.com.br/media/bulas/metformina.pdf.

Diretrizes da Sociedade Brasileira de Diabetes: 2013-2014 [Internet]. São Paulo: AC Farmacêutica; c2014 [acesso em 19 fev. 2015]. Disponível em: http://www.diabetes.org.br/images/pdf/diretrizes-sbd.pdf.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.

Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al. Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mor tal i ty among pat ient s wi th diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892-9.

Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668-75.

Arnouts P, Bolignano D, Nistor I, Bilo H, Gnudi L, Heaf J, et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrol Dial Transplant. 2014;29:1284-300.

Frid A, Sterner GN, Löndahl M, Wiklander C, Cato A, Vinge E, et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33:1291-3.

Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4):CD002967.

Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31:2086-91.

Renda F, Mura P, Finco G, Ferrazin F, Pani L, Landoni G. Metformin-associated lactic acidosis requiring hospitalization: a national 10 year survey and a systematic literature review. Eur Rev Med Pharmacol Sci. 2013;17(suppl 1):45-9.

Kajbaf F, Lalau JD. The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database. Diabet Med. 2013;30:345-8.

van Berlo-van de Laar IR, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther. 2011;36:376-82.

Richy FF, Sabido-Espin M, Guedes S, Corvino FA, Gottwald-Hostalek U. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care. 2014;37:2291-5.

Eppenga WL, Lalmohamed A, Geerts AF, Derijks HJ, Wensing M, Egberts A, et al. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. Diabetes Care. 2014;37:2218-24.

Ekstrom N, Schioler L, Svensson AM, Eeg-Olofsson K, Miao Jonasson J, Zethelius B et al. Effectiveness and safety of metformin in 51675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open. 2012;pii: e001076.

General practice management of type 2 diabetes - 2014-15. Melbourne: The Royal Australian College of General Practitioners and Diabetes Australia; 2014 [ acesso em 20 fev. 2015] . Disponível em: http://www.diabetesaustralia.com.au/PageFiles/763/RACP%20Guidelines%20PDF.pdf

American Diabetes Association. Standards of medical care in diabetes – 2015. Diabetes Care. 2015;38(suppl 1):S1-S94.

Downloads

Published

2015-03-28

How to Cite

1.
Almeida FA de. Metformin use in diabetic patients with chronic renal failure. It is time for change. Rev. Fac. Ciênc. Méd. Sorocaba [Internet]. 2015Mar.28 [cited 2024Jul.6];17(1):1-4. Available from: https://revistas.pucsp.br/index.php/RFCMS/article/view/22265

Issue

Vol. 17 No. 1 (2015)

Section

Update

License

Os autores no momento da submissão transferem os direitos autorais, assim, os manuscritos publicados passam a ser propriedade da revista.

O conteúdo do periódico está licenciado sob uma Licença Creative Commons 4.0, esta licença permite o livre acesso imediato ao trabalho e que qualquer usuário leia, baixe, copie, distribua, imprima, pesquise ou vincule aos textos completos dos artigos, rastreando-os para indexação, passá-los como dados para o software, ou usá-los para qualquer outra finalidade legal.